Canadians raced to get vaccinated against COVID-19 in the first years of the pandemic, but data suggests there’s far less of a rush to get the latest shots available this fall.
Federal figures show only 15 per cent of the population aged five and up had received an updated vaccine by Dec. 3. And while older age groups had higher uptake rates, more than half of higher-risk older adults still hadn’t gotten a dose by early December, either.
Comments closedHealth Canada has authorized an adapted vaccine from Novavax to prevent COVID-19 in people age 12 and older.
The vaccine uses a traditional approach to defend the body against COVID.
It contains a version of the viral spike protein and is also authorized as a booster for those 18 and older, according to Health Canada’s webpage.
Comments closedErin Kissane, a co-founder of the COVID Tracking Project, rolled up her sleeve for the Novavax Covid-19 vaccine in mid-October soon after it was finally recommended in the United States. Like many people with autoimmune diseases, she wants to protect herself from a potentially devastating Covid infection.
Kissane’s autoimmune arthritis seems to make her susceptible to unusual vaccine side effects. After getting an mRNA booster last year, her joints ached so painfully that her doctor prescribed steroids to dampen the inflammation. She still considers the mRNA vaccines “miraculous,” knowing Covid could be far worse than temporary aches.
Comments closedAs the updated COVID vaccines roll out around the country, one more competitor has joined the mix. In early October the U.S. Food and Drug Administration authorized a new booster shot made by the company Novavax. Like the mRNA-based Pfizer and Moderna shots, it targets a SARS-CoV-2 variant, XBB.1.5, which is a descendant of Omicron.
Comments closedEuropean Union (EU) regulators have delayed a decision to give approval for Novavax’s (NVAX.O) variant-tailored COVID-19 vaccine, the Financial Times said on Sunday.
The European Medicines Agency (EMA), which was due to approve the updated vaccine last Friday has requested more information from the company, the FT report added.
Comments closedThe last remaining manufacturer to offer an alternative to mRNA COVID-19 vaccines in Canada is hopeful it will meet the government’s 2024 deadline to make the shots domestically.
Comments closedThe last manufacturer to offer an alternative to COVID-19 mRNA vaccines in Canada hopes to meet the government’s 2024 deadline for domestic dose production.
Novavax, based in Maryland, USA, held a press conference on Wednesday to tout the safety and efficacy of its new vaccine, which targets newer strains of COVID-19.
Comments closedThe Food and Drug Administration announced Tuesday it had authorized Novavax’s updated COVID-19 vaccine, adding a third option for Americans ages 12 and older looking for a new shot this fall and winter.
Comments closedCovid-19 vaccines that have been tweaked to teach the body how to fend off the current crop of circulating variants are now expected to land in drugstores and clinics in mid-September, CDC and FDA officials said.
Comments closed
